NRX Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
NRXP$2.380.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Changes in Stockholders’ Deficit
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’** DEFICIT**
(in thousands, except share data)
| Series A Preferred · Additional · Accumulated Other · Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Preferred Stock · Stock · Common Stock · Paid-in- · Accumulated · Comprehensive · Stockholders’ | ||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Income (Loss) | Deficit | |
| Balance December 31, 2023 | — | $— | 3,000,000 | $3 | 8,391,956 | $8 | $241,406 | $(253,147) | $(3) | $(11,733) |
| Conversion of Series A preferred stock into common stock | — | — | (3,000,000) | (3) | 300,000 | — | 3 | — | — | — |
| At-the-market “ATM” offering, net of offering costs of $197 | — | — | — | — | 385,515 | 1 | 1,626 | — | — | 1,627 |
| Common stock and warrants issued, net of issuance costs $975 | — | — | — | — | 1,273,050 | 1 | 3,256 | — | — | 3,257 |
| Common stock and warrants issued in private placement | — | — | — | — | 270,000 | 1 | 1,026 | — | — | 1,027 |
| Vesting of restricted stock awards | — | — | — | — | 57,500 | — | — | — | — | — |
| Shares issued as repayment of principal and interest for convertible note | — | — | — | — | 3,820,444 | 4 | 5,859 | — | — | 5,863 |
| Issuance of shares related to reverse stock split | — | — | — | — | 73,040 | — | — | — | — | — |
| Contract cost related to Alvogen termination (see Note 8) | — | — | — | — | — | — | 1,336 | — | — | 1,336 |
| Common stock issued in exchange for services | — | — | — | — | 20,000 | — | 37 | — | — | 37 |
| Reclassification of AOCI upon settlement of Streeterville Note | — | — | — | — | — | — | — | — | 3 | 3 |
| Stock-based compensation | — | — | — | — | — | — | 486 | — | — | 486 |
| Net loss | — | — | — | — | — | — | — | (25,126) | — | (25,126) |
| Balance - December 31, 2024 | — | $— | — | $— | 14,591,505 | $15 | $255,035 | $(278,273) | $— | $(23,223) |
| Stock-based compensation | — | — | — | — | — | — | 228 | — | — | 228 |
| Common stock issued in exchange for services | 225,000 | 1 | 600 | — | — | 601 | ||||
| Shares issued as repayment of principal and interest for convertible note | 7,290,898 | 7 | 18,912 | — | — | 18,919 | ||||
| Shares issued with register direct offering, net of offering cost | 5,175,277 | 5 | 9,463 | — | — | 9,468 | ||||
| Fair Value of warrants issued with register direct offering | — | — | — | — | — | — | (3,255) | — | — | (3,255) |
| At-the-market "ATM" offering, net of offering costs | — | — | — | — | 2,276,874 | 2 | 6,390 | — | — | 6,392 |
| Shares issued as a result of repricing under VWAP | — | — | — | — | 303,819 | — | 629 | — | — | 629 |
| Amortization of prepaid offering costs | — | — | — | — | — | — | (161) | — | — | (161) |
| Common stock issued as a result of exercise of warrants | — | — | 1,870,960 | 2 | 3,085 | — | — | 3,087 | ||
| Net loss | — | — | — | — | — | — | (28,622) | (28,622) | ||
| Balance - December 31, 2025 | — | $— | — | $— | 31,734,333 | $32 | $290,926 | $(306,895) | $— | $(15,937) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.